1	F.H.	NNP	2	nn
2	Faulding	NNP	11	nsubj
3	&	CC	2	cc
4	Co.	NNP	2	conj
5	,	,	2	punct
6	an	DT	9	det
7	Australian	JJ	9	amod
8	pharmaceuticals	NNS	9	nn
9	company	NN	2	appos
10	,	,	2	punct
11	said	VBD	0	root
12	its	PRP$	15	poss
13	Moleculon	NNP	14	nn
14	Inc.	NNP	15	nn
15	affiliate	NN	16	nsubj
16	acquired	VBD	11	ccomp
17	Kalipharma	NNP	18	nn
18	Inc.	NNP	16	dobj
19	for	IN	16	prep
20	$	$	19	pobj
21	23	CD	20	number
22	million	CD	20	number
23	.	.	11	punct

1	Kalipharma	NNP	7	nsubj
2	is	VBZ	7	cop
3	a	DT	7	det
4	New	JJ	5	amod
5	Jersey-based	JJ	7	amod
6	pharmaceuticals	NNS	7	nn
7	concern	NN	0	root
8	that	WDT	9	nsubj
9	sells	VBZ	7	rcmod
10	products	NNS	9	dobj
11	under	IN	9	prep
12	the	DT	14	det
13	Purepac	NNP	14	nn
14	label	NN	11	pobj
15	.	.	7	punct

1	Faulding	NNP	2	nsubj
2	said	VBD	0	root
3	it	PRP	4	nsubj
4	owns	VBZ	2	ccomp
5	33	CD	6	num
6	%	NN	4	dobj
7	of	IN	6	prep
8	Moleculon	NNP	11	poss
9	's	POS	8	possessive
10	voting	NN	11	nn
11	stock	NN	7	pobj
12	and	CC	4	cc
13	has	VBZ	4	conj
14	an	DT	15	det
15	agreement	NN	13	dobj
16	to	TO	17	aux
17	acquire	VB	15	infmod
18	an	DT	21	det
19	additional	JJ	21	amod
20	19	CD	21	num
21	%	NN	17	dobj
22	.	.	2	punct

1	That	DT	2	det
2	stake	NN	12	nsubj
3	,	,	2	punct
4	together	RB	5	advmod
5	with	IN	2	prep
6	its	PRP$	10	poss
7	convertible	JJ	9	amod
8	preferred	VBN	9	amod
9	stock	NN	10	nn
10	holdings	NNS	5	pobj
11	,	,	2	punct
12	gives	VBZ	0	root
13	Faulding	NNP	12	iobj
14	the	DT	15	det
15	right	NN	12	dobj
16	to	TO	17	aux
17	increase	VB	15	infmod
18	its	PRP$	19	poss
19	interest	NN	17	dobj
20	to	TO	17	prep
21	70	CD	22	num
22	%	NN	20	pobj
23	of	IN	22	prep
24	Moleculon	NNP	27	poss
25	's	POS	24	possessive
26	voting	NN	27	nn
27	stock	NN	23	pobj
28	.	.	12	punct


